# Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

> **NCT06012266** · PHASE2 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 12 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Dapagliflozin tablet
- **DRUG:** Empagliflozin Tablets

## Key facts

- **NCT ID:** NCT06012266
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-08
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06012266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06012266, "Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06012266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*